Morningstar

Morningstar, Inc.

Equity Bottom-Up

PerkinElmer's fourth-quarter performance mostly tracked our expectations. We do not anticipate any major changes to our fair value estimate after we update our assumptions, and we are leaving our no-moat rating intact. Management slightly lifted its adjusted 2019 EPS guidance range to $4.02-$4.07 (up from $4.00-$4.05) and encompasses our previously forecast $4.02. We view the outlook as realistic as we continue to think the company will benefit from new Cisbio opportunities and broad endmarket…

<p>With myriad acquisitions and divestitures in the past decade, PerkinElmer has been in a constant state of evolution. While the firm’s transformation reduced exposure to cyclical markets and increased focus to environmental and human health offerings, nonstop business shuffling has yet to produce sustainable returns on capital investment. PerkinElmer's competitive positioning has certainly shifted for the better, though, and with several attractive avenues of growth in reach, particularly…</p>

United States

Revvity, Inc. provides health science solutions, technologies, expertise, and services. The Company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and other areas. Revvity serves pharmaceutical and biotech, clinical labs, academia, and governments worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00